Free signup for more
- Track your favorite companies
- Receive email alerts for new filings
- Personalized dashboard of news and more
- Access all data and search results
Filing tables
Filing exhibits
IMMP similar filings
- 2 Dec 25 Immutep to Present New Data from AIPAC-003 Phase II at AIPAC-003 has resulted in successful completion of FDA’s Project Optimus requirements and selection of 30 mg as efti’s optimal biological dose
- 13 Nov 25 EFTISARC-NEO Phase II Highlighted in Oral Presentation at CTOS 2025
- 3 Nov 25 Immutep Receives A$4.6 million R&D Tax Incentive from French Government
- 30 Oct 25 Immutep Quarterly Activities Report & Appendix 4C Q1 FY26
- 21 Oct 25 Two Posters at ESMO Congress 2025 Highlight Immutep’s Focus on Changing Treatment Landscape in First Line Non-Small Cell Lung Cancer
- 20 Oct 25 Current report (foreign)
- 14 Oct 25 Immutep Announces Successful Completion of FDA Project Optimus Requirements
Filing view
External links